Consumer Research
UK Medical Cannabis H1 2025: The Market Still Running on Trust
LONDON – You won't find the echoes of this revolution ...
Virginia Cannabis Licenses Delayed Again After Spanberger Veto
RICHMOND-Virginia’s long-delayed adult-use Cannabis market has suffered another major setback ...
Organigram Reports Q2 Fiscal 2026 Results
TORONTO – Organigram Global Inc. released its financial results, marking a quarter shaped by shifts in consumer preferences and execution issues in key categories. The Canadian producer, known for holding the top market share position ...
Cannabis 3.0: From Getting High to Getting Clinical
NEW YORK-Cannabis is entering a new phase, and this one is about much more than consumption. For decades, Cannabis was trapped in prohibition and treated mainly as a legal problem. Then came commercialization, when Cannabis ...
Vireo Growth Reports Q1 2026 Financial Results
MINNEAPOLIS – Vireo Growth Inc. released its first-quarter 2026 financial results, highlighting the early effects of an active acquisition strategy that has broadened its operations across several key Cannabis markets. The company, which operates a ...
Target Expands Hemp-Derived THC Beverage Sales Area
NEW YORK – Target is broadening its reach in the hemp-derived THC beverage category, adding the products to more than 300 stores across Florida, Texas and parts of Illinois. The mass retailer confirmed the move ...
Cannara Biotech Wraps Up Medican Organic Acquisition
MONTREAL – Cannara Biotech Inc. announced the closing of a transaction to acquire all of the shares of Medican Organic Inc. for an aggregate purchase price of $2.8 million. On the surface, that's a modest ...
Aprio Targets Cannabis Sector in Price Kong Acquisition
ATLANTA-PHOENIX – Aprio, the 20th largest business advisory and accounting firm in the United States, announced it had entered into an agreement to acquire Price Kong, a Phoenix-based CPA and advisory firm. The transaction, effective ...
RYTHM Reports Q1 2026 Financial Results
ROLLING MEADOWS – RHYTHM Inc. disclosed stronger results for the first quarter of 2026 as the company continued its shift toward branded hemp-derived THC products and licensing deals. Revenue from continuing operations came in at ...
Why Metabolic Dysfunction May Be the Next Frontier for Cannabinoid Medicine
NEW YORK- Metabolism is the system that determines how the body produces, distributes, and uses energy, and it sits at the center of modern chronic disease. While it is often reduced to a discussion of ...
Cresco Labs Reports Q1 2026 Financial Results
CHICAGO – Cresco Labs Inc. released its first-quarter results, showcasing the ongoing efforts of one of the largest MSOs to strengthen operations across its footprint while preparing for potential changes at the federal level. With ...
Cronos Group Reports Q1 2026 Financial Results
TORONTO – Cronos Group Inc. posted record net revenue and gross profit for the first quarter of 2026, driven by higher sales volumes, a favorable product mix, and gains in key markets. The Cannabis company ...
Atai Gains Nasdaq Biotechnology Index Spot
NEW YORK – AtaiBeckley N.V., the clinical-stage biopharmaceutical firm born from the November merger of atai Life Sciences and Beckley Psytech, has secured a place in the Nasdaq Biotechnology Index (NBI), a move that underscores ...
Vireo Growth Acquires Eaze, Expands into California and Florida
MINNEAPOLIS – Vireo Growth Inc. announced a definitive agreement to acquire Eaze Inc. in a stock-based transaction valued at $47 million upfront, marking the company's first push into the competitive California and Florida markets. The ...
Massachusetts Cannabis Rollback Gains Legislative Traction
BOSTON – State election officials have validated more than 78,000 signatures for a measure that would dismantle the commercial side of Massachusetts' recreational Cannabis industry, thrusting the issue back into legislative hands just as the ...
U.S. Cannabis Operators Trail Canadian Counterparts in Valuation Metrics, Tied to Tax Constraints
LOS ANGELES – In the ongoing tug-of-war between regulatory challenges and market potential in the Cannabis sector, a fresh analysis underscores how a longstanding IRS provision continues to weigh on American companies. According to Viridian ...
Trump’s Rescheduling Order Ignites State Cannabis Momentum in Pennsylvania, Tennessee, and Wyoming
LOS ANGELES – President Donald Trump's directive last week to fast-track Cannabis's rescheduling has handed lawmakers in several conservative-leaning states a timely political opening to advance Cannabis reforms. The executive order, signed on December 18, ...
Week in Review: Cannabis & Psychedelics Industry Highlights
LOS ANGELES – Operators and investors wrapped up 2025 on a high note, with federal policy breakthroughs and corporate maneuvers signaling sustained growth potential across Cannabis & Psychedelics. Over the past two weeks, President Trump's ...
Texas Awards $50M Grant to Spearhead Ibogaine Trials
AUSTIN – The Texas Health and Human Services Commission has granted $50 million to a statewide consortium led by UTHealth Houston and the University of Texas Medical Branch at Galveston, marking the formal launch of ...
Vireo Growth Acquires PharmaCann Colorado Assets
DENVER – Vireo Growth Inc. reached an agreement with PharmaCann Inc. to buy its 17 operational dispensaries and related assets in Colorado for roughly $49 million in company shares, a move that bolsters Vireo's retail ...
Michigan Senate Tightens Controls on Intoxicating Hemp Derivatives
LANSING – In a bipartisan push to close regulatory gaps, the Michigan Senate approved a package of bills that would classify most high-potency hemp-derived THC items as Cannabis, folding them into the state's established Cannabis ...
Trulieve Secures $140M in Senior Notes
TALLAHASSEE – Trulieve Cannabis Corp. wrapped up a $140 million private placement of 10.5% senior secured notes, tapping into robust investor appetite to fuel its operational push. The deal, upsized from initial plans, comes just ...
🚨🚨 BREAKING: TRUMP RESCHEDULES CANNABIS 🚨🚨
WASHINGTON, D.C. –After months of speculation, President Trump Issues Executive Order Directing Federal Rescheduling of Cannabis to Schedule III President Donald Trump has signed an executive order directing federal agencies to complete the rescheduling of ...
Czech Republic Approves Psilocybin Therapy Guidelines for 2026
PRAGUE – The Czech Republic has taken a measured step toward integrating psychedelic-assisted therapy into its healthcare system, approving detailed rules that will permit the controlled use of psilocybin for select patients beginning in January ...
MSOS ETF Rally Hints at Bigger Gains Ahead, Zuanic Report Finds
LOS ANGELES – A recent report from equity research firm Zuanic & Associates outlines substantial financial gains for U.S. MSOs if federal regulators shift Cannabis to Schedule III status, with savings potentially exceeding hundreds of ...
Organigram Reports Q4 2025 Financial and Full Fiscal Year Results
TORONTO – Organigram Global Inc. released its record Q4 and fiscal 2025 results, showing substantial gains in revenue and profitability metrics despite a quarterly net loss tied to one-time charges. For the fourth quarter, gross ...
The Supreme Court Declines to Resolve Federal Cannabis Prohibition—And the Silence Speaks Volumes
WASHINGTON, D.C. – In its December Orders List, the U.S. Supreme Court declined to hear a case that many hoped would finally force a reckoning between federal Cannabis prohibition and state-legal markets. By declining review, ...
Canopy Growth Acquires MTL Cannabis in Bid to Ramp Up Medical Sales
SMITHS FALLS – Canopy Growth Corp., a major player in the Canadian Cannabis sector, has signed a definitive agreement to purchase MTL Cannabis Corp. in a cash-and-stock transaction worth about $125 million on a fully ...
Trump Sets Plans for Cannabis Reclassification Executive Order
WASHINGTON – President Donald Trump is set to direct federal agencies to reclassify Cannabis from its current Schedule I status to Schedule III under the Controlled Substances Act, a step that would align federal oversight ...
Mid-Cap Cannabis Operators Face Liquidity Pressures Despite Solid Leverage, Viridian Report Finds
LOS ANGELES – Public Cannabis companies with $25-100 million market values are navigating a patchwork of financial strengths and vulnerabilities, according to the latest Weekly Credit Report from Viridian Capital Advisors. It tracks eight U.S.-based ...
Ascend Wellness Partners with Cannabis Advocate for New Dispensary in New Jersey
NEW YORK – Ascend Wellness Holdings Inc. disclosed a partnership with Mister Jones LLC and industry advocate Lerone Jones to launch a retail dispensary in Little Falls, NJ. The arrangement, one of the initial deals ...
Grown Rogue Claims Ground in Minnesota
MINNEAPOLIS – Grown Rogue International Inc., a Сannabis MSO focused on premium flower, has signed a long-term lease for a 109,000-square-foot facility in Fridley, just north of Minneapolis, positioning the company to produce for the ...
New Mexico Speeds Up Psilocybin Therapy Access
SANTA FE – State health leaders in New Mexico outlined plans this week to open a regulated psilocybin therapy program by the close of 2026, advancing the timeline a full year from the original statutory ...
Stiiizy Expands California Retail Network Buying 12 Gold Flora Outlets
LOS ANGELES – Stiiizy, the dominant player in California's Cannabis retail, has taken control of 12 former Gold Flora dispensaries in a $25 million court-approved transaction, marking a key step in the state's ongoing industry ...
Cronos Targets Europe Through Dutch Cannabis Leader Acquisition
TORONTO – Cronos Group Inc. has agreed to buy CanAdelaar B.V., the top supplier in the Netherlands' controlled adult-use Cannabis program, for $67 million upfront plus performance incentives. The move marks Cronos's first major step ...
Craft Cannabis Market Projects Steady Climb to $12.3B by 2031
LOS ANGELES – Small-scale producers in the Cannabis industry are gaining ground as buyers turn toward premium, handcrafted options, with the craft segment expected to double in value over the next five years. A report ...
FDA Signals Shift to Single Phase 3 Trials for Drug Approvals, Opening Door for Faster Psychedelic Therapies
LOS ANGELES – The Food and Drug Administration is preparing to overhaul its evidence requirements for new drug approvals, making a single well-designed Phase 3 trial the standard rather than the exception. This adjustment, outlined ...
